VIOLET

Especialitat

Retina i Vitri

Títol complet

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)

Promotor

Bayer.

Data d'inici

Novembre 2016

Data de finalització

Abril 2017

Investigadors

Principal: Dra. Anniken Burés.